BriaCell stock more than doubles on heavy volume after upbeat update on breast cancer treatment

Shares of BriaCell Therapeutics Corp. more than doubled Wednesday on heavy volume, after the biotechnology company provided upbeat update on its breast cancer treatment. The stock soared 104% to pace all gainers on major U.S. exchanges, while trading volume spiked to 14.9 million shares, compared with the full-day average over the past 30 days of about 520,000 shares. The company the average overall survival benefit was 12.0 months, with a top-responder survival of 21.4 months plus 100% resolution of “eye-bulging” tumor, which compares with average 7.2 months to 9.8 months survival in historical comparison treatment trials. The stock has now gained 55.4% year to date, while the iShares Nasdaq Biotechnology ETF has slipped 0.2% and the S&P 500 has advanced 12.0%.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.